Altimmune Inc (ALT)

$5.13 -0.34 (-6.22%)
Market Cap 617.20M
Revenue (ttm) 20,000.00
Net Income (ttm) -95.06M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -475,300.00%
Debt to Equity Ratio 0.08
Volume 3,557,200
Avg Vol 5,324,786
Day's Range N/A - N/A
Shares Out 112.83M
Stochastic %K 7%
Beta 0.09
Analysts Strong Sell
Price Target $17.78

Company Profile

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

Industry: Biotechnology
Sector: Healthcare
Phone: 240 654 1450
Address:
910 Clopper Road, Suite 201S, Gaithersburg, United States
denzo2
denzo2 Feb. 5 at 5:50 PM
$ALT 😎
0 · Reply
denzo2
denzo2 Feb. 5 at 5:49 PM
$ALT I have analyzed the posts regarding "connections" proving where we are headed. I now understand completely where that is , who the buyer is and who the mystery investor is..see for yourself.
0 · Reply
Lawnmower_Man
Lawnmower_Man Feb. 5 at 5:37 PM
$ALT I had to restart phone to check if the screen was ok as ALT was green in the sea of red...but yep it was green...very
0 · Reply
kadinnguyen
kadinnguyen Feb. 5 at 5:36 PM
$ALT
0 · Reply
TradeSun
TradeSun Feb. 5 at 5:34 PM
$MSFT $LLY $ALT $NVO $QCOM Today's Up&Downgrades
0 · Reply
BigElvis_GTown
BigElvis_GTown Feb. 5 at 5:29 PM
$ALT parting that sea of red today
0 · Reply
Dadschuh14
Dadschuh14 Feb. 5 at 5:28 PM
$ALT However, looking at the structure and our recent high volume. The volume to me has been a short cycle on repeat that has been suppressing the price, hence we haven’t seen the total short go down but also hasn’t increased that much. Also direct seller to buyer large block transactions that hasn’t put pressure on the price. That won’t last forever. Soon there won’t be a seller and the only place will be the lit market that will also not have shares. I suspect the moment we see tutes or big money start buying on the open market this thing will launch. The dealers are set up to step aside when that moment comes.
1 · Reply
Turribull
Turribull Feb. 5 at 5:21 PM
$ALT MM’s be like…😤😂
1 · Reply
Dadschuh14
Dadschuh14 Feb. 5 at 5:18 PM
$ALT That was someone wanting shares and did not go through the normal dark pool to hide. That caught dealers off gaurd and dealers reacted quickly to control. We had flat gamma walls and now they are back right below and above nearest strikes to contain. Makes me wonder if someone just confirmed something and slapped the buy rather than going through the normal exchange. Or someone with a lot of money said "fuck it, I'm in". Ooooor someone just found out they are out a job by our new HR and called their uncle and told them to refinance their house lol Interesting to say the least, but looks like dealers have woken back up to manage.
6 · Reply
lrk3383
lrk3383 Feb. 5 at 5:14 PM
$ALT Need a few more one hit wonders!
1 · Reply
Latest News on ALT
Obesity stocks slump on Novo's underwhelming 2026 sales forecast

Feb 3, 2026, 1:27 PM EST - 1 day ago

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

AMGN GPCR LLY NVO PFE VKTX

Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock

Jan 29, 2026, 5:54 PM EST - 6 days ago

Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock

Altimmune (ALT) Shares Slide On $75 Million Stock Offering

Jan 28, 2026, 4:13 PM EST - 7 days ago

Altimmune (ALT) Shares Slide On $75 Million Stock Offering

Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock

Jan 27, 2026, 9:25 PM EST - 8 days ago

Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock

Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH

Jan 5, 2026, 7:30 AM EST - 4 weeks ago

Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH

Altimmune: Pemvidutide's 48-Week Data Confirms The Market's Smokescreen

Dec 23, 2025, 7:42 PM EST - 6 weeks ago

Altimmune: Pemvidutide's 48-Week Data Confirms The Market's Smokescreen

Altimmune's MASH Drug Shows Durable Liver, Weight Loss Gains At 48 Weeks

Dec 19, 2025, 12:57 PM EST - 6 weeks ago

Altimmune's MASH Drug Shows Durable Liver, Weight Loss Gains At 48 Weeks

Altimmune, Inc. (ALT) Discusses Topline 48-Week Results From IMPACT Phase IIb Trial of Pemvidutide in MASH Transcript

Dec 19, 2025, 11:37 AM EST - 6 weeks ago

Altimmune, Inc. (ALT) Discusses Topline 48-Week Results From IMPACT Phase IIb Trial of Pemvidutide in MASH Transcript

Altimmune's drug for a type of liver disease shows benefits in mid-stage study

Dec 19, 2025, 6:42 AM EST - 6 weeks ago

Altimmune's drug for a type of liver disease shows benefits in mid-stage study

Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial

Dec 19, 2025, 6:30 AM EST - 6 weeks ago

Altimmune Announces that Pemvidutide Achieved Key Measures of Success at 48 Weeks in IMPACT Phase 2b MASH Trial

Altimmune Announces CEO Transition and Succession Plan

Dec 1, 2025, 7:30 AM EST - 2 months ago

Altimmune Announces CEO Transition and Succession Plan

Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference

Nov 26, 2025, 7:30 AM EST - 2 months ago

Altimmune to Participate in the Piper Sandler 37th Annual Healthcare Conference

Altimmune, Inc. (ALT) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 20, 2025, 3:03 PM EST - 2 months ago

Altimmune, Inc. (ALT) Presents at Jefferies London Healthcare Conference 2025 Transcript

Altimmune: Probing Pemvi's MASH Data

Nov 14, 2025, 3:23 AM EST - 2 months ago

Altimmune: Probing Pemvi's MASH Data

Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025

Nov 11, 2025, 8:51 AM EST - 3 months ago

Altimmune Announces Publication of IMPACT Phase 2b Trial Data in The Lancet and Concurrent Late-Breaking Oral Presentation at AASLD The Liver Meeting® 2025

Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025

Nov 7, 2025, 8:05 AM EST - 3 months ago

Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025

Altimmune, Inc. (ALT) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 2:26 PM EST - 3 months ago

Altimmune, Inc. (ALT) Q3 2025 Earnings Call Transcript

Altimmune Announces Third Quarter 2025 Financial Results and Business Updates

Nov 6, 2025, 7:00 AM EST - 3 months ago

Altimmune Announces Third Quarter 2025 Financial Results and Business Updates

Altimmune to Participate in Two Upcoming Investor Conferences

Nov 5, 2025, 7:30 AM EST - 3 months ago

Altimmune to Participate in Two Upcoming Investor Conferences

Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder

Nov 3, 2025, 7:30 AM EST - 3 months ago

Altimmune Announces Early Completion of Enrollment in RECLAIM Phase 2 Trial Evaluating Pemvidutide in Alcohol Use Disorder

Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025

Oct 30, 2025, 7:30 AM EDT - 3 months ago

Altimmune to Report Third Quarter 2025 Financial Results and Provide Business Update on November 6, 2025

Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025

Oct 20, 2025, 7:30 AM EDT - 3 months ago

Altimmune to Present Phase 2b IMPACT Data on Pemvidutide in MASH in Late-Breaking Oral Podium Presentation and Late-Breaking Poster at AASLD The Liver Meeting® 2025

ALTIMMUNE FINAL DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Urges Investors to Contact the Firm Regarding the October 6th Deadline

Oct 6, 2025, 10:09 AM EDT - 4 months ago

ALTIMMUNE FINAL DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Urges Investors to Contact the Firm Regarding the October 6th Deadline

ALT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Oct 5, 2025, 11:40 PM EDT - 4 months ago

ALT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Oct 3, 2025, 9:50 AM EDT - 4 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Sep 30, 2025, 10:20 AM EDT - 4 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide

Sep 29, 2025, 7:30 AM EDT - 4 months ago

Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Sep 21, 2025, 8:39 AM EDT - 4 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune

Bragar Eagel & Squire, P.C. Reminds Investors of Altimmune and SelectQuote that Lawsuits Have Been Filed and Encourages Investors to Contact the Firm

Sep 19, 2025, 10:27 AM EDT - 4 months ago

Bragar Eagel & Squire, P.C. Reminds Investors of Altimmune and SelectQuote that Lawsuits Have Been Filed and Encourages Investors to Contact the Firm

SLQT

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 6, 2025 in Altimmune, Inc. Lawsuit - ALT

Sep 18, 2025, 8:45 AM EDT - 5 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 6, 2025 in Altimmune, Inc. Lawsuit - ALT

Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer

Sep 15, 2025, 7:30 AM EDT - 5 months ago

Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer

Altimmune, Inc. (ALT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 11:20 AM EDT - 5 months ago

Altimmune, Inc. (ALT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Altimmune: Is There Still Hope For Pemvidutide? I Believe There Is (Upgrade)

Aug 27, 2025, 5:17 PM EDT - 5 months ago

Altimmune: Is There Still Hope For Pemvidutide? I Believe There Is (Upgrade)

Altimmune to Participate in Upcoming Investor Conferences

Aug 26, 2025, 7:30 AM EDT - 5 months ago

Altimmune to Participate in Upcoming Investor Conferences

Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)

Aug 19, 2025, 7:30 AM EDT - 6 months ago

Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD)

Berger Montague PC Investigates Securities Claims Against Altimmune, Inc. (NASDAQ: ALT)

Aug 15, 2025, 12:06 PM EDT - 6 months ago

Berger Montague PC Investigates Securities Claims Against Altimmune, Inc. (NASDAQ: ALT)

denzo2
denzo2 Feb. 5 at 5:50 PM
$ALT 😎
0 · Reply
denzo2
denzo2 Feb. 5 at 5:49 PM
$ALT I have analyzed the posts regarding "connections" proving where we are headed. I now understand completely where that is , who the buyer is and who the mystery investor is..see for yourself.
0 · Reply
Lawnmower_Man
Lawnmower_Man Feb. 5 at 5:37 PM
$ALT I had to restart phone to check if the screen was ok as ALT was green in the sea of red...but yep it was green...very
0 · Reply
kadinnguyen
kadinnguyen Feb. 5 at 5:36 PM
$ALT
0 · Reply
TradeSun
TradeSun Feb. 5 at 5:34 PM
$MSFT $LLY $ALT $NVO $QCOM Today's Up&Downgrades
0 · Reply
BigElvis_GTown
BigElvis_GTown Feb. 5 at 5:29 PM
$ALT parting that sea of red today
0 · Reply
Dadschuh14
Dadschuh14 Feb. 5 at 5:28 PM
$ALT However, looking at the structure and our recent high volume. The volume to me has been a short cycle on repeat that has been suppressing the price, hence we haven’t seen the total short go down but also hasn’t increased that much. Also direct seller to buyer large block transactions that hasn’t put pressure on the price. That won’t last forever. Soon there won’t be a seller and the only place will be the lit market that will also not have shares. I suspect the moment we see tutes or big money start buying on the open market this thing will launch. The dealers are set up to step aside when that moment comes.
1 · Reply
Turribull
Turribull Feb. 5 at 5:21 PM
$ALT MM’s be like…😤😂
1 · Reply
Dadschuh14
Dadschuh14 Feb. 5 at 5:18 PM
$ALT That was someone wanting shares and did not go through the normal dark pool to hide. That caught dealers off gaurd and dealers reacted quickly to control. We had flat gamma walls and now they are back right below and above nearest strikes to contain. Makes me wonder if someone just confirmed something and slapped the buy rather than going through the normal exchange. Or someone with a lot of money said "fuck it, I'm in". Ooooor someone just found out they are out a job by our new HR and called their uncle and told them to refinance their house lol Interesting to say the least, but looks like dealers have woken back up to manage.
6 · Reply
lrk3383
lrk3383 Feb. 5 at 5:14 PM
$ALT Need a few more one hit wonders!
1 · Reply
Turribull
Turribull Feb. 5 at 5:13 PM
$ALT Check on your Crypto bros. They’re not okay.
6 · Reply
SuperPuncher
SuperPuncher Feb. 5 at 5:11 PM
$ALT pump in no way tethered to $XBI today Something’s up
0 · Reply
Hatrak1
Hatrak1 Feb. 5 at 5:10 PM
$ALT
0 · Reply
SuperSuper
SuperSuper Feb. 5 at 5:09 PM
$ALT face
1 · Reply
Jcordless
Jcordless Feb. 5 at 5:08 PM
$ALT ALTians!!!!
0 · Reply
roadto2M
roadto2M Feb. 5 at 5:08 PM
$ALT
0 · Reply
SuperPuncher
SuperPuncher Feb. 5 at 5:08 PM
$ALT what’s going on ?
0 · Reply
Muskvoice
Muskvoice Feb. 5 at 5:08 PM
$ALT NEED 5.30$ TO BE GOOD
0 · Reply
thedentite
thedentite Feb. 5 at 5:07 PM
$ALT YYYAAAAYYY
0 · Reply
kyothehardest
kyothehardest Feb. 5 at 5:06 PM
$ALT
0 · Reply
blankstocker
blankstocker Feb. 5 at 5:06 PM
$ALT The only two stocks in my portfolio that are green right now happen to be two of the stocks that were given a dollar price target by GS. Just sayin.
0 · Reply
Fullydrawn
Fullydrawn Feb. 5 at 5:05 PM
$ALT Let's go!
0 · Reply